> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Ebola Vaccine BLA Under Priority Review
- URL: https://www.fdaweb.com/merck-ebola-vaccine-bla-under-priority-review/
- Published: 2019-09-17T12:00:00.000Z
- Updated: 2026-09-15T01:50:30.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5145020

FDA has accepted for priority review a Merck BLA for its investigational Ebola vaccine (V920) for preventing disease caused by the Ebola Zaire virus. The agency has set a 3/14/2020 user fee review action target dated. In July 2016, FDA granted Breakthrough Therapy Designation to V920.

While developing the vaccine, Merck says it has scaled-up vaccine doses being produced to help international public health officials and government authorities meet ongoing outbreak response needs in the Democratic Republic of the Congo and neighboring countries. Since 5/2018, the company says it has donated and shipped more than 245,000 V920 in response to requests by the World Health Organization.